The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy, and in parallel, drives improved T cell effector function. The company is advancing AMV564 through Phase 1 clinical development across multiple solid tumor indications and hematologic malignancies.
Cyborg Score Rationale
Amphivena demonstrates a validated technology platform with clinical proof-of-concept (Phase 1 data showing complete response), significant institutional backing ($88.5M raised), and a strategic focus on immuno-oncology—a high-value market segment. However, the company remains pre-clinical to early clinical stage with limited recent public data (last major update June 2021), modest headcount (17 employees as of 2026), and no evidence of partnership or accelerated development milestones.
Top Insights
Founded in 2012, Amphivena emerged from Affimed spinco structure, signaling technology licensing or spin-off origins
Phase 1 data support dose and schedule of AMV564 for expansion cohorts in selected solid tumor indications, indicating advancement readiness as of June 2021
The company has 17 total employees (as of 2026), suggesting limited infrastructure and potential outsourced clinical/manufacturing operations
Amphivena Therapeutics raised a total of $88.5M, with Series C funding completed in September 2019
Named Competitors
BiTE Platform — Established bispecific T-cell engager platform for hematologic malignancies
(June 2021) Presented comprehensive Phase 1 monotherapy and first combination therapy clinical data at ASCO Annual Meeting for AMV564 in solid tumor patients
(December 2020) Announced first patient dosed in Phase 1 dose expansion study of AMV564
(September 2019) Closed $62 million Series C financing round co-led by NanoDimension and Qiming Venture Partners
Open the full interactive Amphivena Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.